These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26155603)

  • 1. Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2015 Jul; 80(130):38915-40. PubMed ID: 26155603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administrative Destruction of Certain Drugs Refused Admission to the United States. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2015 Sep; 80(178):55237-42. PubMed ID: 26387150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategic plan aims to curb drug shortages.
    Cancer Discov; 2014 Jan; 4(1):7. PubMed ID: 24402927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of certain drug products by registered blood establishments and comprehensive hemophilia diagnostic treatment centers that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements and administrative procedures. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Oct; 73(197):59496-501. PubMed ID: 18985968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administrative detention of drugs intended for human or animal use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2014 May; 79(103):30716-21. PubMed ID: 24873018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of blood derivatives by registered blood establishments that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; delay of applicability date. Final rule; delay of applicability date.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Nov; 71(218):66108-9. PubMed ID: 17099971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supplements and other changes to an approved application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Apr; 69(68):18727-67. PubMed ID: 15072041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amendment of regulations regarding certain label statements on prescription drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Feb; 67(22):4904-7. PubMed ID: 11829025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conforming regulations regarding removal of section 507 of the Federal Food, Drug, and Cosmetic Act; confirmation of effective date. Food and Drug Administration, HHS. Direct final rule; confirmation of effective date.
    Fed Regist; 1999 May; 64(94):26657. PubMed ID: 10558515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarification of When Products Made or Derived From Tobacco Are Regulated as Drugs, Devices, or Combination Products; Amendments to Regulations Regarding "Intended Uses." Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2017 Jan; 82(5):2193-217. PubMed ID: 28071877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical devices; reports of corrections and removals--FDA. Direct final rule.
    Fed Regist; 1998 Aug; 63(152):42229-33. PubMed ID: 10181725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. List of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Mar; 64(44):10944-7. PubMed ID: 10557618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule.
    Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical devices; establishment registration and device listing for manufacturers and distributors of devices--FDA. Direct final rule.
    Fed Regist; 1998 Sep; 63(188):51825-7. PubMed ID: 10185812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical Devices; Custom Devices; Technical Amendment. Final rule; technical amendment.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Oct; 81(197):70339-40. PubMed ID: 27731963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical devices; humanitarian use of devices--FDA. Direct final rule.
    Fed Regist; 1998 Apr; 63(74):19185-90. PubMed ID: 10178430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.